Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris

Review

(2097) Views  (516) Full article downloads

Authors: Efstratios Vakirlis, Athanasios Kastanis, Demetrios Ioannides

Published Date March 2008 Volume 2008:4(1) Pages 141 - 148

DOI: http://dx.doi.org/10.2147/TCRM.S1478

Efstratios Vakirlis, Athanasios Kastanis, Demetrios Ioannides

A’ Department of Dermatology, Aristotle University of Thessaloniki, Greece

Abstract: Psoriasis is one of the most common skin diseases. The mainstay of treatment for the vast majority of patients is topical therapy. A rising first-line treatment modality for psoriasis vulgaris is the two-compound ointment containing calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g (Dovobet^®, Daivobet^®, Taclonex^®), which combines a vitamin D analog and a corticosteroid. This innovative formulation preserves the activity and bioavailability of the two components and many clinical studies have demonstrated that it has a greater efficacy, tolerability, and a rapid onset of action compared with its individual ingredients or tacalcitol.

Keywords: psoriasis, calcipotriol/betamethasone dipropionate, dovobet, daivobet, taclonex